These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 15040939)

  • 1. Recombinant antibodies: a natural partner in combinatorial antifungal therapy.
    Matthews RC; Burnie JP
    Vaccine; 2004 Feb; 22(7):865-71. PubMed ID: 15040939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifungal antibodies: a new approach to the treatment of systemic candidiasis.
    Matthews R; Burnie J
    Curr Opin Investig Drugs; 2001 Apr; 2(4):472-6. PubMed ID: 11566001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efungumab: a novel agent in the treatment of invasive candidiasis.
    Karwa R; Wargo KA
    Ann Pharmacother; 2009 Nov; 43(11):1818-23. PubMed ID: 19773528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human recombinant antibody to HSP90: a natural partner in combination therapy.
    Matthews RC; Burnie JP
    Curr Mol Med; 2005 Jun; 5(4):403-11. PubMed ID: 15977996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis.
    Pachl J; Svoboda P; Jacobs F; Vandewoude K; van der Hoven B; Spronk P; Masterson G; Malbrain M; Aoun M; Garbino J; Takala J; Drgona L; Burnie J; Matthews R;
    Clin Infect Dis; 2006 May; 42(10):1404-13. PubMed ID: 16619152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.
    Queiroz-Telles F; Berezin E; Leverger G; Freire A; van der Vyver A; Chotpitayasunondh T; Konja J; Diekmann-Berndt H; Koblinger S; Groll AH; Arrieta A;
    Pediatr Infect Dis J; 2008 Sep; 27(9):820-6. PubMed ID: 18679151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential of anti-Candida antibodies in immunoprophylaxis.
    Cabezas J; Albaina O; Montañez D; Sevilla MJ; Moragues MD; Pontón J
    Immunotherapy; 2010 Mar; 2(2):171-83. PubMed ID: 20635926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
    Rieger CT; Dittmer M; Ostermann H
    Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined treatment: antifungal drugs with antibodies, cytokines or drugs.
    Stevens DA; Kullberg BJ; Brummer E; Casadevall A; Netea MG; Sugar AM
    Med Mycol; 2000; 38 Suppl 1():305-15. PubMed ID: 11204158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifungal immunotherapy and immunomodulation: a double-hitter approach to deal with invasive fungal infections.
    Hamad M
    Scand J Immunol; 2008 Jun; 67(6):533-43. PubMed ID: 18397201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of liposomal amphotericin B in bone marrow transplant.
    Sastry PS; Parikh PM; Kulkarni PS; Bhagwat R; Gadade H
    J Postgrad Med; 2005; 51 Suppl 1():S49-52. PubMed ID: 16519256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetically recombinant antibodies: new therapeutics against candidiasis.
    Burnie J; Matthews R
    Expert Opin Biol Ther; 2004 Feb; 4(2):233-41. PubMed ID: 14998780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
    Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of efficacy trials of cytokines in combination with antifungal drugs.
    Kullberg BJ; Oude Lashof AM; Netea MG
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S218-23. PubMed ID: 15546121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newer antifungal agents for invasive fungal infections in patients with haematological malignancy.
    Rogers TR; Frost S
    Br J Haematol; 2009 Mar; 144(5):629-41. PubMed ID: 19120371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The third age of antimicrobial therapy.
    Casadevall A
    Clin Infect Dis; 2006 May; 42(10):1414-6. PubMed ID: 16619153
    [No Abstract]   [Full Text] [Related]  

  • 17. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions.
    Safdar A; Rodriguez GH; Lichtiger B; Dickey BF; Kontoyiannis DP; Freireich EJ; Shpall EJ; Raad II; Kantarjian HM; Champlin RE
    Cancer; 2006 Jun; 106(12):2664-71. PubMed ID: 16691620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of solid organ transplant patients with invasive fungal infections: should a combination of antifungal drugs be used?
    Muñoz P; Singh N; Bouza E
    Curr Opin Infect Dis; 2006 Aug; 19(4):365-70. PubMed ID: 16804385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of invasive fungal infections in immunocompromised and transplant patients: AmBiLoad trial and other new data.
    Muñoz P; Guinea J; Narbona MT; Bouza E
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S125-31. PubMed ID: 19013336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose range evaluation of Mycograb C28Y variant, a human recombinant antibody fragment to heat shock protein 90, in combination with amphotericin B-desoxycholate for treatment of murine systemic candidiasis.
    Louie A; Stein DS; Zack JZ; Liu W; Conde H; Fregeau C; Vanscoy BD; Drusano GL
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3295-304. PubMed ID: 21502626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.